Danaher Non-GAAP EPS of $2.11 beats by $0.19, revenue of $6.55B misses by $10M (DHR:NYSE)

Danaher (DHR) reported Q3 Non-GAAP EPS of $2.11, beating estimates by $0.19, while revenue of $6.55B missed by $10M. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62, up from $8.45-$8.60. Danaher also announced Julie Sawyer Montgomery as its new CEO, effective October 1.

Original reporting
Published Oct 21, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DHR
Bullish
high confidence
Mentioned
$DHR
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$DHRBullishHigh
01

Why it matters

The earnings beat and guidance lift suggest a bullish short‑term catalyst for DHR.

02

Market read

The new earnings data provides a fresh trading signal for DHR and may influence related industrial stocks.

03

What to watch

Potential supply‑chain constraints or macro‑economic headwinds could temper upside despite the guidance raise.

Relevance 9/10Novelty 9/10Timing: after‑hours release

Background

Danaher is a diversified science and technology company; the Q3 results were released via a press release on Seeking Alpha.

Company-level read

Ticker impact

$DHRBullishHigh confidence
Context

Danaher reported Q3 Non‑GAAP EPS of $2.11, beating expectations by $0.19 and raised full‑year adjusted EPS guidance to $8.57‑$8.62.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The surprise EPS beat and upward revision of full‑year earnings are material new information for a large‑cap industrial conglomerate.

Market effects

May lift other life‑sciences and industrial automation peers as earnings beat signals demand strength.

Positive for U.S. large‑cap industrial sector.

Limited to investors tracking global industrial conglomerates.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Danaher Corporation

    US‑listed industrial conglomerate reporting Q3 results.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.